Investigational drug · Phase 3
VCT220
Also called: CX11
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Type 2 Diabetes Mellitus (DM), Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
11
Any phase or sponsor naming "VCT220"
First trial start
2024
Dec 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VCT220", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Type 2 Diabetes Mellitus (DM)
- Hypertension
- Type II Diabetes Mellitus
- Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "VCT220" as an intervention, largest first.
- A Research Study of VCT220 in Adult Chinese Participants With ObesityPivotal-lookingCompleted
Vincentage Pharma Co., LtdIndustry
NCT06939296 · 840 participants · Start Dec 24, 2024 · Primary completion Nov 25, 2025
Drug: VCT220; Placebo · For: Obesity; Overweight
Sites: Beijing, China
- A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
Corxel PharmaceuticalsIndustry
NCT07340320 · 251 participants · Start Feb 6, 2026 · Primary completion Apr 8, 2027
Drug: CX11 · For: Type II Diabetes Mellitus
Sites: Birmingham, Alabama; Huntsville, Alabama; Cerritos, California · 44 sites in all
- A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese ParticipantsPivotal-lookingCompleted
Corxel PharmaceuticalsIndustry
NCT07011797 · 250 participants · Start Jun 17, 2025 · Primary completion Mar 23, 2026
Drug: CX11 · For: Obesity
Sites: Phoenix, Arizona; Inglewood, California; San Diego, California · 17 sites in all
- A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese PopulationPivotal-lookingCompleted
Vincentage Pharma Co., LtdIndustry
NCT06569355 · 250 participants · Start Dec 27, 2023 · Primary completion Jul 13, 2024
Drug: VCT220; Placebo · For: Obesity; Overweight
Sites: Beijing, China
- A Study of VCT220 in Participants With Hypertension and Obesity or OverweightPivotal-lookingActive, not recruiting
Vincentage Pharma Co., LtdIndustry
NCT07360275 · 160 participants (planned) · Start Mar 1, 2026 · Primary completion Oct 30, 2026
Drug: VCT220 Tablet; VCT220 Placebo Tablet · For: Hypertension
Sites: Beijing, China · 2 sites in all
- A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose ControlPivotal-lookingNot yet recruiting
Vincentage Pharma Co., LtdIndustry
NCT07872436 · 120 participants (planned) · Start Nov 1, 2026 · Primary completion Jul 1, 2027
Drug: VCT220 tablets; Placebo · For: Type 2 Diabetes Mellitus (DM)
Sites: Beijing, China
Vincentage Pharma Co., LtdIndustry
NCT07056842 · 32 participants · Start Jul 20, 2025 · Primary completion Aug 11, 2025
Drug: Rifampin + VCT220; Itraconazole + VCT220 · For: Obesity &Amp; Overweight
Sites: Jinan, China
Vincentage Pharma Co., LtdIndustry
NCT07349381 · 32 participants · Start Mar 4, 2026 · Primary completion Jun 30, 2026
Drug: CX11 (VCT220) · For: Obesity & Overweight; Type 2 Diabetes
Sites: Shanghai, China
Vincentage Pharma Co., LtdIndustry
NCT07065058 · 24 participants · Start Jul 1, 2025 · Primary completion Jul 11, 2025
Drug: Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin · For: Obesity &Amp; Overweight
Sites: Chengdu, China
- A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic FunctionCompleted
Vincentage Pharma Co., LtdIndustry
NCT06938529 · 24 participants · Start Apr 18, 2025 · Primary completion Jul 15, 2025
Drug: VCT220; Placebo · For: Obesity, Overweight
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.
Ji L, Gao L, Li B, et al. · Signal Transduct Target Ther 2026
- Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
Randall L, Xiang Y, Matsumoto T, et al. · Gynecol Oncol 2025
- Processivity and enzymatic mechanism of a non-modular family 5 endoglucanase from Sporocytophaga sp. CX11 with potential applications in cellulose saccharification.
Chen X, Gao Z, Wang S, et al. · Enzyme Microb Technol 2025
- Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?
Penninx BMF, Samson MJ, Schnog JB · Cancer 2025
- Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials.
Zhang X, Shen J, Huang M, et al. · Front Immunol 2024
- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lorusso D, Xiang Y, Hasegawa K, et al. · Lancet 2024
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.